Stay Connected. Stay Informed.
A view of Dr. Reddy’s Lab facility near Hyderabad | Photo Credit: The Hindu The U.S. Food and Drug Administration (U.S. FDA) has issued two observations to a manufacturing facility of Dr. Reddy’s Laboratories in Andhra Pradesh. A Form 483 with the two observations was issued by the U.S. FDA on completion of a pre-approval…
Read More “Dr. Reddy’s facility in Andhra Pradesh gets 2 U.S. FDA observations” »
A step-down wholly owned U.S. subsidiary of pharma major Dr. Reddy’s Laboratories has been levied a $32,350.20 penalty by the U.S. Internal Revenue Service (IRS). The penalty on Dr. Reddy’s Laboratories Inc., the subsidiary, is due to misclassification of fiscal year reference at the time of tax payment, the Hyderabad-based parent company said citing the…
Read More “U.S. IRS imposes $32,350 penalty on Dr. Reddy’s arm” »
While Dr. Reddy’s will exclusively manage private-market distribution, disease awareness, and healthcare professional engagement, Takeda will retain rights for the public market, legal ownership, and overall medical and brand oversight. File | Photo Credit: Reuters Dr. Reddy’s Laboratories on Friday (September 18, 2026) entered into an exclusive distribution agreement with Takeda Pharmaceutical Company to promote…
Read More “Dr. Reddy’s, Takeda Pharma ink pact to distribute India’s first dengue vaccine QDENGA” »
Dr. Reddy’s Laboratories on Tuesday said it is foraying into the biosimilar immuno-oncology therapy segment in India with the launch of Nivorz, a biosimilar of Bristol Myers Squibb’s Opdivo (nivolumab). The biosimilar has been developed and manufactured entirely in-house at its biologics facility in Bachupally, Hyderabad. The launch reflects the company’s end-to-end capabilities across the…
Read More “Dr. Reddy’s forays into India’s biosimilar immuno-oncology market, launches Nivorz” »
Dr. Reddy’s Labs | Photo Credit: The Hindu Contract research, development and manufacturing organisation Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy’s Laboratories, has entered into a long-term manufacturing and supply agreement (MSA) with a leading global pharmaceutical company. Under the agreement, Aurigene will undertake commercial drug-product manufacturing and supply for a diversified portfolio targeting…
Dr. Reddy’s Laboratories has ended its more than four-year relationship with Novartis India, terminating an agreement under which it distributed and promoted select brands of the Swiss drugmaker in India. The termination of the February 11, 2022, agreement follows a change in the controlling shareholding of Novartis India. It will continue to commercialise the brands…
Read More “Dr. Reddy’s, Novartis India terminate agreement” »
A view of Dr. Reddy’s Lab facility near Hyderabad. | Photo Credit: The Hindu Dr. Reddy’s Laboratories has been issued three observations by the U.S. Food and Drug Administration (U.S. FDA) after an inspection of its facility in Srikakulam, Andhra Pradesh. The U.S. FDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP)…
Read More “Dr. Reddy’s Srikakulam facility gets 3 U.S. FDA observations” »
Hyderabad-based generic drugmaker Dr. Reddy’s Laboratories’ consolidated net profit slumped 69% year-on-year (YoY) to ₹.435.6 crore in the June quarter amid lower sales of cancer drug lenalidomide and nearly ₹240 crore provision necessitated by recent quality issue around weight loss drug Semaglutide. Total revenue from operations stood at ₹8,099.8 crore (₹8,572.1 crore), showed its results…
Read More “Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue” »
A view of Dr. Reddy’s Laboratories in Hyderabad. Dr. Reddy’s Laboratories announced on Saturday (June 13, 2026 ) the first-to-market launch of Bosutinib Tablets 400 mg, a generic equivalent of Pfizer subsidiary Wyeth’s cancer drug Bosulif, in the U.S. Bosutinib Tablets (400mg) was a first-to-file product and thus eligible for 180-days of generic drug exclusivity…
Read More “Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.” »
